Taken together, these results indicated that mutant KRAS is dispensable for pleural tumour growth, but important for MPE development and for the associated systemic recruitment of CD11b+Gr1+ myeloid cells, and suggested that KRAS must be responsible for the secretion of a solute mediator of MPE by tumour cells. Here, ITGAM is linked to pleural neoplasm.